A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India

Inclusion Criteria:

• Signed consent obtained before any study-related activities (study-relatedactivities are any procedure related to recording of data according to theprotocol).

• Diagnosed with type 2 diabetes (T2D).

• The decision to initiate treatment with commercially available oral semaglutide hasbeen made by the patient/Legally Acceptable Representative (LAR) and the treatingphysician based on local label before and independently from the decision to includethe patient in this study.

• Male or female, age above or equal to 18 years at the time of signing informedconsent.

• Available glycated haemoglobin A1c (HbA1c) value less than or equal to (<=) 90 daysprior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1cmeasurement taken in relation with the 'Informed Consent and Treatment Initiationvisit' (V1) if in line with local clinical practice.

• Treatment naive to injectable glucose-lowering drug(s). An exception is short-terminsulin treatment for acute illness for a total of less than or equal to (<=) 14days.

Exclusion Criteria:

• Previous participation in this study. Participation is defined as having giveninformed consent in this study.

• Any prior or current use of oral semaglutide.

• Hypersensitivity to oral semaglutide or to any of the excipients.

• Treatment with any investigational drug within 30 days prior to signing of informedconsent.

• Participation in any clinical trial of an approved or non-approved investigationalmedicinal product within 30 days prior to signing of informed consent.

• Mental incapacity, unwillingness or language barriers precluding adequateunderstanding or cooperation.